FORMULATION DEVELOPMENT AND INVITRO EVALUATION OF ESOMEPRAZOLE CONTROLLED RELEASE TABLETS BY USING VARIOUS GRADES OF EUDRAGIT POLYMERS

The aim of the contemporary research work was to develop the controlled release tablets of esomeprazole. Esomeprazole having a shorter biological half life (1-1.5 hours) hence we are selected as a controlled release tablet, So it should be minimize the dose dumping problems and avoid fluctuations in plasma drug concentrations. To maintain constant therapeutic levels of the drug over 24 hours. Compatibility studies was execution during FTIR and DSC shown that there was absence of probable chemical interaction between pure drug and excipients. Controlled release tablets were prepared by direct compression method using altered concentrations of Eudragit-S 100, Eudragit-L 100 and Eudragit-RSPO. Esomeprazole dose was fixed as 20 mg. Total weight of the tablet was considered as 100 mg. Polymers were used in the concentration of 20 and 40 mg. Prepared compositions were evaluating the various physicochemical parameters such as weight variation, hardness, friability, thickness and drug content. All the compositions were resulted in adequate Pharmacopoeial limits. Whereas from the dissolution studies it was evident that the formulation (F-6) showed better desired drug release pattern i.e., 97.47% in 24 hours. It followed Zero Order release kinetics mechanism. As the consequence of this amendment it could conclude that the compositions rally the needed theoretical drug release profile as well as has the controlled action i.e., retarded the drug release, Hence so the release is for a long time and thus more Bioavailability. The optimised formula shall be utilized for the formulation development and other studies like bioequivalence study, for triumphant initiation of the product